MA29731B1 - Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne - Google Patents
Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienneInfo
- Publication number
- MA29731B1 MA29731B1 MA30618A MA30618A MA29731B1 MA 29731 B1 MA29731 B1 MA 29731B1 MA 30618 A MA30618 A MA 30618A MA 30618 A MA30618 A MA 30618A MA 29731 B1 MA29731 B1 MA 29731B1
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- tyroidian
- receptor agonists
- hormone receptor
- pyridazinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSÉS DE LA FORMULE (I) ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CES DERNIERS, LES SUBSTITUANTS ÉTANT TELS QUE MENTIONNÉS DANS LA DESCRIPTION. LES COMPOSÉS PRÉCITÉS, ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, SONT UTILISÉS DANS LE TRAITEMENT DE MALADIES TELLES QUE L'OBÉSITÉ, L'HYPERLIPIDÉMIE, L'HYPERCHOLESTÉROLÉMIE ET LE DIABÈTE ET AUTRES AFFECTIONS ET MALADIES LIÉES, ET PEUVENT ÊTRE UTILISÉS POUR D'AUTRES MALADIES TELLES QUE LA STÉATO-HÉPATITE NON ALCOOLIQUE (NASH), L'ATHÉROSCLÉROSE, LES MALADIES CARDIOVASCULAIRES, L'HYPOTHYROÏDIE, LE CANCER DE LA THYROÏDE ET AUTRES AFFECTIONS ET MALADIES LIÉES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70121505P | 2005-07-21 | 2005-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29731B1 true MA29731B1 (fr) | 2008-09-01 |
Family
ID=37114368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30618A MA29731B1 (fr) | 2005-07-21 | 2008-02-01 | Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne |
Country Status (32)
Country | Link |
---|---|
US (3) | US7452882B2 (fr) |
EP (1) | EP1919878B1 (fr) |
JP (1) | JP5000649B2 (fr) |
KR (1) | KR100965006B1 (fr) |
CN (1) | CN101228135B (fr) |
AR (1) | AR054848A1 (fr) |
AT (1) | ATE480524T1 (fr) |
AU (1) | AU2006271721C1 (fr) |
BR (1) | BRPI0613754B8 (fr) |
CA (1) | CA2614529C (fr) |
CR (1) | CR9644A (fr) |
CY (1) | CY1110929T1 (fr) |
DE (1) | DE602006016821D1 (fr) |
DK (1) | DK1919878T3 (fr) |
EC (1) | ECSP088120A (fr) |
ES (1) | ES2349131T3 (fr) |
HK (1) | HK1115129A1 (fr) |
HR (1) | HRP20100633T1 (fr) |
IL (1) | IL188476A (fr) |
MA (1) | MA29731B1 (fr) |
MX (1) | MX2008000818A (fr) |
MY (1) | MY142861A (fr) |
NO (1) | NO340679B1 (fr) |
NZ (1) | NZ565190A (fr) |
PL (1) | PL1919878T3 (fr) |
PT (1) | PT1919878E (fr) |
RS (1) | RS51639B (fr) |
RU (1) | RU2379295C2 (fr) |
TW (1) | TWI330636B (fr) |
UA (1) | UA88104C2 (fr) |
WO (1) | WO2007009913A1 (fr) |
ZA (1) | ZA200800405B (fr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051298A2 (fr) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Nouvelles substances thyromimetiques contenant du phosphore |
EP1604988A1 (fr) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Dérivés de pyridazinone, méthodes de leur préparation et leur utilisation comme pharmaceutiques |
US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
DK1919878T3 (da) | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
JPWO2008133141A1 (ja) * | 2007-04-24 | 2010-07-22 | 東洋紡績株式会社 | オスモチン組換えタンパク質およびその製造方法、並びにその利用 |
SI2061766T1 (sl) | 2007-06-06 | 2010-12-31 | Torrent Pharmaceuticals Ltd | Nove spojine |
US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
CA2704714C (fr) | 2007-11-15 | 2018-12-04 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Derives de pyridazinone inhibiteurs de la parp |
KR100981781B1 (ko) | 2008-02-29 | 2010-09-10 | 재단법인 한국원자력의학원 | 방사선 치료용 콜리메이터 장치 및 그 장치를 이용한방사선 치료장치 |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
WO2010122980A1 (fr) | 2009-04-20 | 2010-10-28 | 田辺三菱製薬株式会社 | Nouvel agoniste du récepteur ss de l'hormone thyroïdienne |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
JP5847533B2 (ja) * | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
EP2683704B1 (fr) | 2011-03-08 | 2014-12-17 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
BR112015005891A2 (pt) * | 2012-09-17 | 2017-08-08 | F Hoffmann La Roche Ltd | método de sintetizar análogos do hormônio da tireoide e polimorfos destes |
CN105272927A (zh) * | 2015-11-17 | 2016-01-27 | 华中药业股份有限公司 | 一种制备氯氮卓的新方法 |
KR20190109387A (ko) | 2016-10-18 | 2019-09-25 | 마드리갈 파마슈티칼스, 인크. | Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법 |
WO2018094265A2 (fr) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Méthodes de traitement de glycogénose |
BR112019025659A2 (pt) | 2017-06-05 | 2020-08-25 | Viking Therapeutics, Inc. | composições para o tratamento de fibrose |
US20210154370A1 (en) | 2017-09-14 | 2021-05-27 | Riken | Method for producing retinal tissues |
CN111646979B (zh) * | 2018-01-23 | 2021-08-31 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
CA3095872A1 (fr) | 2018-04-16 | 2019-10-24 | Ioulia Tseti | Composition pharmaceutique de poudre seche pour inhalation comprenant une hormone thyroidienne |
BR112020022146A2 (pt) | 2018-06-12 | 2021-01-26 | Fronthera U.S. Pharmaceuticals Llc | compostos da fórmula e composição farmacêutica |
US20210292304A1 (en) * | 2018-06-22 | 2021-09-23 | Hinova Pharmaceuticals Inc. | Deuterated mgl-3196 compound and use thereof |
AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
EP3840755A4 (fr) | 2018-08-24 | 2022-04-20 | Terns, Inc. | Composés agonistes des récepteurs bêta des hormones thyroïdiennes |
CN113164498A (zh) * | 2018-09-06 | 2021-07-23 | 盖尔梅德研究与发展有限公司 | 用于肝病的治疗的组合疗法 |
JP2022504706A (ja) * | 2018-10-12 | 2022-01-13 | インベンティスバイオ カンパニー リミテッド | 甲状腺ホルモン受容体作動薬 |
WO2020077123A1 (fr) * | 2018-10-12 | 2020-04-16 | Terns, Inc. | Composés agonistes du récepteur bêta des hormones thyroïdiennes |
CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
CN111592528A (zh) * | 2019-02-20 | 2020-08-28 | 苏州泽璟生物制药股份有限公司 | 氘代的哒嗪酮及其衍生物和药物组合物 |
WO2020169069A1 (fr) | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Nouveaux composés et leurs utilisations en tant qu'agonistes du récepteur de l'hormone thyroïdienne |
EP3939662A4 (fr) | 2019-03-13 | 2023-03-15 | Sumitomo Pharma Co., Ltd. | Procédé d'évaluation de la qualité d'une rétine neurale de transplantation, et feuille de rétine neurale de transplantation |
BR112021021718A2 (pt) * | 2019-05-08 | 2022-01-18 | Aligos Therapeutics Inc | Moduladores de thr-ss e métodos de uso dos mesmos |
TW202108556A (zh) * | 2019-05-10 | 2021-03-01 | 大陸商深圳微芯生物科技股份有限公司 | 一種噠嗪酮衍生物及其應用 |
WO2020239076A1 (fr) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | DÉRIVÉS DE PYRIDAZINONE CONSTITUANT DES AGONISTES DU RÉCEPTEUR DE LA THYROXINE DE TYPE β ET LEUR UTILISATION |
WO2021032218A1 (fr) | 2019-08-19 | 2021-02-25 | 苏州闻天医药科技有限公司 | COMPOSÉ AGONISTE DU RÉCEPTEUR THR-β HÉTÉROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION |
CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
CA3154488A1 (fr) * | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Composes agonistes du recepteur beta de l'hormone thyroidienne |
WO2021043185A1 (fr) * | 2019-09-04 | 2021-03-11 | Sunshine Lake Pharma Co., Ltd. | Composé utilisé comme agoniste du récepteur bêta des hormones thyroïdiennes et son utilisation |
AU2020346057A1 (en) * | 2019-09-12 | 2022-04-21 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
US20220411400A1 (en) * | 2019-09-24 | 2022-12-29 | Sunshine Lake Pharma Co., Ltd. | Chemical compound as thyroid hormone beta receptor agonist and use thereof |
CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
JP2023503154A (ja) * | 2019-11-26 | 2023-01-26 | 昆薬集団股▲フン▼有限公司 | 1,2,4-トリアジン-3,5-ジオン系化合物およびその製造方法と応用 |
WO2021129465A1 (fr) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | Cristal de resmétirom, son procédé de préparation et ses utilisations |
CN113045551B (zh) * | 2019-12-27 | 2024-07-09 | 广东东阳光药业股份有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
JP2023510835A (ja) | 2020-01-13 | 2023-03-15 | エコジーン (シャンハイ) カンパニー リミテッド | 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン |
CN113278013B (zh) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
CN113698388B (zh) * | 2020-05-20 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
KR20230048481A (ko) | 2020-06-02 | 2023-04-11 | 쳉두 캉홍 파마슈티칼 코., 엘티디. | 새로운 갑상선 호르몬 β 수용체 효능제 |
US20230339911A1 (en) * | 2020-08-27 | 2023-10-26 | InventisBio Co., Ltd. | Pyridazinone compounds |
US20230416234A1 (en) * | 2020-09-10 | 2023-12-28 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of resmetirom, preparation method therefor, and use thereof |
WO2022053028A1 (fr) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation |
WO2022054924A1 (fr) | 2020-09-11 | 2022-03-17 | 大日本住友製薬株式会社 | Milieu pour tissu destiné à la transplantation |
JPWO2022054925A1 (fr) | 2020-09-11 | 2022-03-17 | ||
TW202220977A (zh) * | 2020-09-30 | 2022-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 6-側氧-1,6-二氫噠嗪類衍生物、其製備方法及其在醫藥上的應用 |
EP4204419A1 (fr) | 2020-10-19 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Formes solides de resmetirom |
TW202233605A (zh) | 2020-11-06 | 2022-09-01 | 美商艾利格斯醫療公司 | 雙環嗒𠯤酮及其使用方法 |
CN112645936B (zh) * | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | 取代的哒嗪酮类化合物及其用途 |
CN114685450A (zh) * | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1,2,4-三嗪-3,5-二酮类化合物的盐型、晶型及其制备方法 |
CA3238664A1 (fr) | 2021-11-19 | 2023-05-25 | Riken | Procede de production de tissu retinien en forme de feuille |
WO2024084491A1 (fr) * | 2022-10-21 | 2024-04-25 | Mehta Nilesh Vipinchandra | Procédé de synthèse de res metirom et de ses intermédiaires |
CN115650928B (zh) * | 2022-12-28 | 2023-03-31 | 凯思凯旭(上海)医药科技有限公司 | 一种多环类甲状腺激素β受体激动剂及其用途 |
WO2024141076A1 (fr) * | 2022-12-29 | 2024-07-04 | Gannex Pharma Co., Ltd. | Promédicaments pour analogues d'hormones thyroïdiennes et leur procédé de fabrication et d'utilisation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582842A (en) * | 1981-02-25 | 1986-04-15 | Merck & Co., Inc. | Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor |
GB8501372D0 (en) | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
EP0728482A3 (fr) | 1995-02-10 | 1999-10-20 | Smithkline Beecham Corporation | Emploi de composés HCP spécifiques pour augmenter l'érythropoiese |
KR100271513B1 (ko) | 1995-06-06 | 2000-12-01 | 디. 제이. 우드 | 2,4-디클로로피리딘을 2-아릴옥시-4-클로로피리딘으로 전환시키기 위한 방법 |
CA2225668A1 (fr) | 1995-06-30 | 1997-01-23 | Damien John Dunnington | Utilisation de composes specifiques du domaine stat 6 sh2 pour le traitement des reactions allergiques |
US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
YU63301A (sh) * | 1999-03-01 | 2004-09-03 | Pfizer Products Inc. | Oksaminske kiseline i njihovi derivati kao ligandi tiroidnog receptora |
CA2433100A1 (fr) * | 2000-12-27 | 2002-07-04 | Helmut Haning | Derives de l'indole utilises comme ligands de recepteurs de la thyroide |
CA2435820A1 (fr) * | 2001-02-08 | 2002-08-15 | Karo Bio Ab | Nouveaux ligands de recepteurs thyroidiens |
EP1236720B1 (fr) * | 2001-02-28 | 2005-06-15 | Pfizer Products Inc. | Derives de sulfonyl-pyridazinone comme inhibiteurs de reductase d'aldose |
WO2005051298A2 (fr) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Nouvelles substances thyromimetiques contenant du phosphore |
JP4627315B2 (ja) * | 2004-03-23 | 2011-02-09 | エフ.ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体 |
DK1919878T3 (da) | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
-
2006
- 2006-07-11 DK DK06792493.6T patent/DK1919878T3/da active
- 2006-07-11 ES ES06792493T patent/ES2349131T3/es active Active
- 2006-07-11 PT PT06792493T patent/PT1919878E/pt unknown
- 2006-07-11 MX MX2008000818A patent/MX2008000818A/es active IP Right Grant
- 2006-07-11 EP EP06792493A patent/EP1919878B1/fr active Active
- 2006-07-11 JP JP2008521935A patent/JP5000649B2/ja active Active
- 2006-07-11 PL PL06792493T patent/PL1919878T3/pl unknown
- 2006-07-11 AU AU2006271721A patent/AU2006271721C1/en active Active
- 2006-07-11 RU RU2008106058/04A patent/RU2379295C2/ru active
- 2006-07-11 DE DE602006016821T patent/DE602006016821D1/de active Active
- 2006-07-11 BR BRPI0613754A patent/BRPI0613754B8/pt active IP Right Grant
- 2006-07-11 CA CA2614529A patent/CA2614529C/fr active Active
- 2006-07-11 CN CN2006800267317A patent/CN101228135B/zh active Active
- 2006-07-11 WO PCT/EP2006/064093 patent/WO2007009913A1/fr active Application Filing
- 2006-07-11 NZ NZ565190A patent/NZ565190A/en unknown
- 2006-07-11 RS RS20100527A patent/RS51639B/en unknown
- 2006-07-11 KR KR1020087001480A patent/KR100965006B1/ko active IP Right Grant
- 2006-07-11 AT AT06792493T patent/ATE480524T1/de active
- 2006-07-18 US US11/488,870 patent/US7452882B2/en active Active
- 2006-07-18 TW TW095126242A patent/TWI330636B/zh active
- 2006-07-19 AR ARP060103084A patent/AR054848A1/es active IP Right Grant
- 2006-07-19 MY MYPI20063456A patent/MY142861A/en unknown
- 2006-11-07 UA UAA200801933A patent/UA88104C2/ru unknown
-
2007
- 2007-12-27 IL IL188476A patent/IL188476A/en active IP Right Grant
-
2008
- 2008-01-04 NO NO20080058A patent/NO340679B1/no unknown
- 2008-01-08 CR CR9644A patent/CR9644A/es unknown
- 2008-01-14 ZA ZA2008/00405A patent/ZA200800405B/en unknown
- 2008-01-18 EC EC2008008120A patent/ECSP088120A/es unknown
- 2008-02-01 MA MA30618A patent/MA29731B1/fr unknown
- 2008-08-20 US US12/194,643 patent/US7807674B2/en active Active
- 2008-09-17 HK HK08110278.4A patent/HK1115129A1/xx unknown
-
2010
- 2010-11-22 CY CY20101101049T patent/CY1110929T1/el unknown
- 2010-11-23 HR HR20100633T patent/HRP20100633T1/hr unknown
-
2015
- 2015-07-01 US US14/788,921 patent/USRE46024E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29731B1 (fr) | Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne | |
MA31087B1 (fr) | Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde. | |
MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
MA29909B1 (fr) | Derives de pyridazine | |
TNSN08445A1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
MA28747B1 (fr) | Dérivés de pyridine | |
TNSN97193A1 (fr) | Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA27728A1 (fr) | Antagonistes des recepteurs de cgrp | |
MA30602B1 (fr) | Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
MA29550B1 (fr) | Derives de n- (pyridine-2-yl) - sulfonamide | |
MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
MA29148B1 (fr) | Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
MA33056B1 (fr) | Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
MA27883A1 (fr) | Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
MA30601B1 (fr) | Modulateurs de metabolisme et traitement de troubles metaboliques | |
MA31419B1 (fr) | Derives de pyridine | |
MA33219B1 (fr) | Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation |